Evidence map›Paper›PMID 31158383›Full record

ArticleExperimental eye research2019

Increased serum proteins in non-exudative AMD retinas.

Hannah Schultz, Ying Song, Bailey H Baumann, Rebecca J Kapphahn, Sandra R Montezuma, Deborah A Ferrington, Joshua L Dunaief

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Dynamic Inner Blood Retina Barrier Disruption in Retinitis Pigmentosa.Investigative ophthalmology & visual science · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hannah SchultzF.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, 422 Curie Blvd, Philadelphia, PA, 19104, USA.
Ying SongF.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, 422 Curie Blvd, Philadelphia, PA, 19104, USA.
Bailey H BaumannF.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, 422 Curie Blvd, Philadelphia, PA, 19104, USA.
Rebecca J KapphahnDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, 55455, USA.
Sandra R MontezumaDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, 55455, USA.
Deborah A FerringtonDepartment of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN, 55455, USA.
Joshua L DunaiefF.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, 422 Curie Blvd, Philadelphia, PA, 19104, USA. Electronic address: jdunaief@pennmedicine.upenn.edu.
University of Minnesota · USUniversity of Pennsylvania · USPenn Presbyterian Medical Center · US

Funding

Retinal Iron Transport in Health and DiseaseR01EY015240 · NEI · UNIVERSITY OF PENNSYLVANIA · PI JOSHUA L DUNAIEF · 2004 to 2026
$10.4M
VMD-PhD Training in Infectious Disease-Related ResearchT32AI070077 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael Lee Atchison · 2008 to 2026
$3.5M
The IL-6 Induced Retinal Iron Sequestration ResponseR01EY028916 · NEI · UNIVERSITY OF PENNSYLVANIA · PI DUNAIEF, JOSHUA L · 2019 to 2023
$2.4M
Age-related macular degeneration,mitochondria and the CFH genotypeR01EY026012 · NEI · UNIVERSITY OF MINNESOTA · PI FERRINGTON, DEBORAH ANN · 2016 to 2019
$1.7M
NEI NIH HHS R01 EY015240NEI NIH HHS R01 EY026012NEI NIH HHS R01 EY028916NIAID NIH HHS T32 AI070077
6 · The paper itself

Abstract

The blood retinal barrier (BRB) closely regulates the retinal microenvironment. Its compromise leads to the accumulation of retinal fluid containing potentially harmful plasma components. While eyes with non-exudative age-related macular degeneration (AMD) were previously felt to have an intact BRB, we propose that the BRB in non-exudative AMD eyes may be subclinically compromised, allowing entry of retina-toxic plasma proteins. We test this hypothesis by measuring retinal levels of abundant plasma proteins that should not cross the intact BRB. Two cohorts of frozen, post mortem neurosensory retinas were studied by Western analysis. One cohort from Alabama had 4 normal controls and 4 eyes with various forms of AMD. Another cohort from Minnesota had 5 intermediate AMD eyes and 5 normals. Both cohorts were age/post mortem interval (PMI) matched. The non-exudative AMD retinas in the Alabama cohort had significantly higher levels of albumin and complement component 9 (C9) than normal controls. The positive control exudative AMD donor retina had higher levels of all but one serum protein. In both macular and peripheral neurosensory retina samples, intermediate AMD retinas in the Minnesota cohort had significantly higher levels of albumin, fibrinogen, IgG, and C9 than controls. Our results suggest that there may be moderate subclinical BRB leakage in non-exudative AMD. Potentially harmful plasma components including complement or iron could enter the neurosensory retina in AMD patients prior to advanced disease. Thus, therapies aiming to stabilize the BRB might have a role in the management of non-exudative AMD.

Indexed as

AgedAged, 80 and overBlood ProteinsBlood-Retinal BarrierBlotting, WesternComplement C9Exudates and TransudatesFemaleFibrinogenGeographic AtrophyHumansImmunoglobulin GMaleRetinaSerum AlbuminBlood ProteinsComplement C9FibrinogenImmunoglobulin GSerum AlbuminAge-related macular degeneration (AMD)AlbuminBlood retinal barrier (BRB)Complement factor 9 (C9)FibrinogenIgGIronRetina

Identifiers

PMID31158383
PMCPMC6703940
OpenAlexW2948030328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.